

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 3

Application No.	10/817,591
Filing Date	April 2, 2004
First Named Inventor	Sallberg, et al.
Art Unit	1648
Examiner	Bao Q. Li
Attorney Docket No.	TRIEP.23AUS2C1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/BL/ ↓	1	4,215,051	7/29/1980	Schroeder et al.	
	2	4,376,110	3/8/1983	David et al.	
	3	4,486,530	12/4/1984	David et al.	
	4	4,683,195	7/28/1987	Mullis et al.	
	5	4,683,202	7/28/1987	Mullis, Kary B.	
	6	4,818,540	4/4/1989	Chien, et al.	
	7	4,873,191	10/10/1989	Wagner et al.	
	8	4,965,188	10/23/1990	Mullis, Kary B.	
	9	5,143,854	9/1/1992	Pirung et al	
	10	5,290,678	3/1/1994	Jackowski	
	11	5,322,770	6/21/1994	Gelfand	
	12	5,412,087	5/2/1995	McGall et al.	
	13	5,604,105	2/18/1997	Jackowski	
	14	5,710,008	1/20/1998	Jackowski	
	15	5,744,358	4/28/1998	Jackowski	
	16	5,747,274	5/5/1998	Jackowski	
	17	5,847,101	12/1/1998	Okayama et al	
	18	2004/0092730	5/13/2004	Sallberg, Matti	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
/BL/ ↓	19	WO 90/15070	12/13/1990	Affymax Technologies N.V.		
	20	WO 92/10092	6/25/1992	Affymax Technologies N.V.		
	21	WO 94/11530	5/26/1994	Trustees of Boston University		
	22	WO 94/12305	6/9/1994	Gühring, et al.		
	23	WO 95/11995	5/4/1995	Affymax Technologies N.V.		
	24	WO 97/29212	8/14/1997	Affymetrix, Inc.,		

Examiner Signature	/Bao Li/	Date Considered	03/02/2007
--------------------	----------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i>	Application No.	10/817,591
	Filing Date	April 2, 2004
	First Named Inventor	Sallberg, et al.
	Art Unit	1648
SHEET 2 OF 3		Attorney Docket No. TRIPEP.23AUS2C1

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	25	WO 97/31256	8/28/1997	Louisiana State University		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/BL/	26	Bitter et al., <i>Methods in Enzymol.</i> , 153:516-544 (1987)	
	27	BLASTN 2.2.9., May 1, 2004	
	28	Chang et al., <i>Aliment Pharmacol Ther.</i> 2002 Sep; 16(9): 1623-1632	
	29	Colberre-Garapin, et al., "A new dominant hybrid selective marker for higher eukaryotic cells," <i>J. Mol. Biol.</i> 150:1 (1981)	
	30	Cote et al., "Generation of human monoclonal antibodies reactive with cellular antigens" <i>Proc Natl. Acad. Sci.</i> , 80:2026-2030 (1983)	
	31	Davis et al., <i>Human Gene Therapy</i> , 4(6):733 (1993)	
	32	Engvall, E., <i>Meth. Enzymol.</i> , 70:419 (1980)	
	33	Fodor et al., <i>Science</i> , 251:767-773 (1991)	
	34	Heagy et al., <i>J. Clin. Invest.</i> 1991, Vol. 87, pp. 1916-1924	
	35	Hosoya et al., <i>J. INF. Dis.</i> , 168:641-646 (1993)	
	36	Houghten et al., <i>Proc. Natl. Acad. Sci. USA</i> , 82:51:32 (1985)	
	37	Hultgren et al., <i>Clin. Diagn. Lab. Immunol.</i> 4:630-632 (1997)	
	38	Huse W.D. et al. <i>Science</i> 256:1275-1281 (1989)	
	39	Hutchison et al., <i>Proc. Natl. Acad. Sci. USA</i> 253:6551 (1978)	
	40	Janknecht, et al., <i>Proc. Natl. Acad. Sci. USA</i> 88:8972-8976 (1991)	
✓	41	Kozbor et al., <i>Immunol Today</i> 4:72 (1983)	

Examiner Signature	/Bao Li/	Date Considered	03/02/2007
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/817,591
	Filing Date	April 2, 2004
	First Named Inventor	Sallberg, et al.
	Art Unit	1648
(Multiple sheets used when necessary)	Examiner	Bao Q. Li
SHEET 3 OF 3	Attorney Docket No.	TRIPEP.23AUS2C1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/BL/	42	Lo, <i>Mol. Cell. Biol.</i> 3:1803-1814 (1983)	
	43	Logan & Shenk, <i>Proc. Natl. Acad. Sci. USA</i> 81:3655-3659 (2000)	
	44	Lowy, et al., <i>Cell</i> 22:817 (1980)	
	45	Morrison et al. <i>Proc. Natl. Acad. Sci. USA</i> 81:6851-6855 (1984)	
	46	Mulligan & Berg, <i>Proc. Natl. Acad. Sci. USA</i> 78:2072 (1981)	
	47	O'Hare, et al., <i>Proc. Natl. Acad. Sci. USA</i> 78:1527 (1981)	
	48	Orlandi et al., <i>Proc. Natl. Acad. Sci.</i> 86: 3833-3837 (1989)	
	49	Ruther et al., <i>EMBO J.</i> , 2:1791 (1983)	
	50	Santerre et al., <i>Gene</i> . 30:147 (1984)	
	51	Steigerwald-Mullen et al., <i>J. Virol.</i> 2000, Vol. 74, No. 15, pp. 6748-6759	
	52	Thompson et al., <i>Cell</i> 56:313-321 (1989)	
	53	Townsend et al., <i>J. Virol.</i> 71:3365 (1997)	
	54	Van der Putten et al., <i>Proc. Natl. Acad. Sci., USA</i> 82:6148-6152 (1985)	
	55	Wigler et al., <i>Cell</i> 11:223 (1977)	
	56	Wigler et al., <i>Proc. Natl. Acad. Sci. USA</i> 77:3567 (1980)	
↓	57	Winter G. and Milstein C; <i>Nature</i> 349:293-299 (1991)	

3329302
011907

Examiner Signature	/Bao Li/	Date Considered	03/02/2007
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i>	Application No.	10/817,591
	Filing Date	April 2, 2004
	First Named Inventor	Sallberg et al.
	Art Unit	1648
	Examiner	Bao Q. Li
SHEET 4 OF 7	Attorney Docket No.	TRIPEP.23AUS2C1

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
BCI	84	WO 97/26883	07/31/97	WIPO		
	85	WO 98/16184	04/23/98	WIPO		
	86	WO 98/16186	04/23/98	WIPO		
✓	87	WO 98/30223	07/16/98	WIPO		

class
subkeys

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
BCI	88	AASLD Abstracts 940, "Hepatitis C Virus NS5A Sequence Configuration does not Predict Response to Induction Interferon Plus Ribavirin," <i>Hepatology</i> , p. 394A (2000).	
	89	Abrignani et al., "Perspectives for a vaccine against hepatitis C virus," <i>Journal of Hepatology</i> , 31: (suppl. 1):259-263 (1999).	
	90	Bartenschlager et al., "Substrate Determinants for Cleavage in cis and in trans by the Hepatitis C Virus NS3 Proteinase," <i>Journal of Virology</i> , pp. 198 - 205, (1995).	
	91	Chen et al., "Detection of Hepatitis C Virus RNA in the Cell Fraction of Saliva Before and After Oral Surgery," <i>J. Med. Virol.</i> , 43:223-226 (1995).	
	92	Chen et al., "Human and Murine Antibody Recognition is Focused on the ATPase/Helicase, but not the Protease Domain of the Hepatitis C Virus Nonstructural 3 Protein," <i>Hepatology</i> , 28(1):219-224 (1998).	
	93	Chiang et al., "Enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response by ribavirin correlates with the increased level of IL-2," <i>Vaccine Strategies Against Microbial Pathogens</i> , 42:11-42:16, p. A949 (date unknown).	
	94	Cotonat et al., "Pilot Study of Combination Therapy with Ribavirin and Interferon Alfa for the Retreatment of Chronic Hepatitis B e Antibody-Positive Patients," <i>Hepatology</i> , 31(2):502-506 (2000).	
	95	Cramp et al., "Hepatitis C Virus-Specific T-Cell Reactivity During Interferon and Ribavirin Treatment in Chronic Hepatitis C," <i>Gastron. Enterol.</i> , 118:346-355 (2000)	
	96	Diepolder et al., "Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection," <i>Lancet</i> , 346(8981):1006-1007.	
	97	Encke et al., "Genetic Immunization Generates Cellular and Humoral Immune Responses Against the Nonstructural Proteins of the Hepatitis C Virus in a Murine Model," <i>Journal of Immunology</i> , 161:4917-4923 (1998).	
	98	Fang et al., "Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level," <i>Journal of Hepatology</i> , 33(5):791-798 (2000).	
	99	Gordon et al., "Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations," <i>Journal of Infectious Diseases</i> , 181(1):42-50. (2000)	
✓	100	Grakoui et al., "A second hepatitis C virus-encoded proteinase," <i>Proc. Natl. Acad. Sci USA</i> , 90:10583-10587, (1993).	

Examiner Signature	B Q Li	Date Considered	02/13/2006
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

T¹ - Place a check mark in this area when an English language Translation is attached.